Article

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

2020-08-06

Abstract excerpt

<h4>Background</h4> NVX-CoV2373 is a recombinant nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins. We present the Day 35 primary analysis of our trial of NVX-CoV2373 with or without the saponin-based Matrix-M1 adjuvant in healthy adults. <h4>Methods</h4> This is a randomized, observer-blinded, placebo-controlled, phase 1 trial in 131 healthy adults. Trial vaccination comprised t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1655d06e-98dd-56a6-8215-3379880855cd
DOI: 10.1101/2020.08.05.20168435

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineDOI 10.1101/2020.08.05.20168435Read

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in miceSemantic proximity Read

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled TrialSemantic proximity Read

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in miceSemantic proximity Read

First-in-Human Trial of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine with Adjuvant of Aluminum Hydroxide and CpG 1018Semantic proximity Read

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 VariantSemantic proximity Read

Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 Recombinant Spike Protein VaccineSemantic proximity Read

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variantsSemantic proximity Read

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: randomised, active-controlled, observer-blinded, phase 3 trialSemantic proximity Read

Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in PlantsSemantic proximity Read

Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03Semantic proximity Read

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trialSemantic proximity Read

Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trialSemantic proximity Read